M Gómez García

DAREON-8: Updated efficacy and safety from a phase I dose-escalation/expansion trial of first-line (1L) obrixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma (ES-SCLC).

Solange Peters, Rafal Dziadziuszko, Ewa Kalinka, Anas Gazzah et autres

8089 Background: Obrixtamig (BI 764532) is a DLL3/CD3 IgG-like T-cell engager that has shown promising efficacy in ES-SCLC, as monotherapy and in combination with other agents. Due to the aggressiveness of ES-SCLC, early initiation of optimal 1L induction therapy is critical, as …

ch, pl, fr, es, us, cn (code pays fourni par la source)

Abstract CT193: Intracranial activity of ZL-1310, a DLL3-targeted ADC, in patients with previously treated extensive-stage small cell lung cancer and baseline brain metastasis: Analysis of a phase 1 trial

Pedro Rocha, Manish R. Patel, Yi-Long Wu, Jun Zhao et autres

Abstract Background: Brain metastasis (BM) is prevalent in extensive-stage small-cell lung cancer (ES-SCLC) and also a common cause for treatment failure. BM remains as an unmet need with limited treatment options available such as palliative radiotherapy. ZL-1310 is a novel antibody-drug conjugate …

es, us, cn, Éthiopie (code pays fourni par la source)

Exocrine Pancreatic Function in Pediatric Patients After Two Years of Triple CFTR Modulator Therapy: Is It Possible to Restore Pancreatic Function?

Concepción Marina López Cárdenes, S. Vicente Santamaría, R. García Romero, A. Tabares González et autres

BACKGROUND: Improvement in exocrine pancreatic function in people with Cystic fibrosis (PwCF) after ivacaftor and lumacaftor/ivacaftor has been documented. Data on triple therapy with elexacaftor/tezacaftor/ivacaftor (ETI) are limited. METHODS: In this multicenter, prospective, observational study, we reviewed changes in fecal elastase-1 (FE-1) …

es (code pays fourni par la source)

Hepatitis aguda por irbesartán

JR Foruny Olcina, VF Moreira Vicente, M Gómez García, JL Morell Hita

es (code pays fourni par la source)